Adverse drug events in the oral cavity

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 119, Issue 1, 2015, Pages 35-47

  Yuan, Anna ^a,b   Woo, Sook Bin ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; MOUTH; MOUTH DISEASE;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOUTH; MOUTH DISEASES;

EID: 84915748264     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oooo.2014.09.009     Document Type: Review

References (220)

1. I.R. Edwards, and J.K. Aronson Adverse drug reactions: definitions, diagnosis, and management Lancet 356 2000 1255 1259
2. J.R. Nebeker, P. Barach, and M.H. Samore Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting Ann Intern Med 140 2004 795 801
3. F. Femiano, R. Rullo, F. di Spirito, A. Lanza, V.M. Festa, and N. Cirillo A comparison of salivary substitutes versus a natural sialogogue (citric acid) in patients complaining of dry mouth as an adverse drug reaction: a clinical, randomized controlled study Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112 2011 e15 e20
4. A.I. Zavras, G.E. Rosenberg, J.D. Danielson, and V.M. Cartsos Adverse drug and device reactions in the oral cavity: surveillance and reporting J Am Dent Assoc 144 2013 1014 1021
5. C. Scully, and J.V. Bagan Adverse drug reactions in the orofacial region Crit Rev Oral Biol Med 15 2004 221 239
6. A. Villa, and S. Abati Risk factors and symptoms associated with xerostomia: a cross-sectional study Aust Dent J 56 2011 290 295
7. M.J. Korstanje Drug-induced mouth disorders Clin Exp Dermatol 20 1995 10 18
8. N. Lavanya, P. Jayanthi, U.K. Rao, and K. Ranganathan Oral lichen planus: an update on pathogenesis and treatment J Oral Maxillofac Pathol 15 2011 127 132
9. S.O. Piboonniyom, N. Treister, W. Pitiphat, and S.B. Woo Scoring system for monitoring oral lichenoid lesions: a preliminary study Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 2005 696 703
10. V. Van den Haute, J.L. Antoine, and J.M. Lachapelle Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples Dermatologica 179 1989 10 13
11. S.K. Lowell Goldsmith, Barbara Gilchrest, Amy Paller, David Leffell, and Klaus Wolff Fitzpatrick's Dermatology in General Medicine 8th ed. 2012 McGraw-Hill Professional Boston, MA
12. C. Fessa, P. Lim, S. Kossard, S. Richards, and P.F. Penas Lichen planus-like drug eruptions due to beta-blockers: a case report and literature review Am J Clin Dermatol 13 2012 417 421
13. S. Halevy, and A. Shai Lichenoid drug eruptions J Am Acad Dermatol 29 1993 249 255
14. L.A. Reinhardt, J.K. Wilkin, and W.M. Kirkendall Lichenoid eruption produced by captopril Cutis 31 1983 98 99
15. S.M. Breathnach Mechanisms of drug eruptions: Part I Australas J Dermatol 36 1995 121 127
16. P.B. Sugerman, N.W. Savage, X. Zhou, L.J. Walsh, and M. Bigby Oral lichen planus Clin Dermatol 18 2000 533 539
17. M. Baricevic, M. Mravak Stipetic, and M. Situm Oral bullous eruption after taking lisinopril - case report and literature review Cent Eur J Med 125 2013 408 411
18. B.J. Schlosser Lichen planus and lichenoid reactions of the oral mucosa Dermatol Ther 23 2010 251 267
19. G. Artico, I.S. Bruno, J. Seo, S.K. Hirota, R. Acay, and D.A. Migliari Lichenoid reaction to carbamazepine in the oral mucosa: case report An Bras Dermatol 86 2011 S152 S155
20. D. Grinspan, J. Diaz, and L.O. Villapol [Lichen ruber planus of the buccal mucosa. Its association with diabetes] Bull Soc Fr Dermatol Syphiligr 73 1966 898 899
21. S.H. Aljabre Grinspan's syndrome J Am Acad Dermatol 30 1994 671
22. C. Kragelund, C. Hansen, and J. Reibel Polymorphic drug metabolizing CYP-enzymes-a pathogenic factor in oral lichen planus? J Oral Pathol Med 38 2009 63 71
23. C. Kragelund, C. Hansen, and J. Reibel Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions? J Oral Pathol Med 39 2010 497 505
24. B.E. McCartan, and C.E. McCreary Oral lichenoid drug eruptions Oral Dis 3 1997 58 63
25. M.H. Thornhill, V. Sankar, and X.J. Xu The role of histopathological characteristics in distinguishing amalgam-associated oral lichenoid reactions and oral lichen planus J Oral Pathol Med 35 2006 233 240
26. M. Siponen, L. Huuskonen, E. Laara, and T. Salo Association of oral lichen planus with thyroid disease in a Finnish population: a retrospective case-control study Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110 2010 319 324
27. J. Robledo-Sierra, U. Mattsson, and M. Jontell Use of systemic medication in patients with oral lichen planus - a possible association with hypothyroidism Oral Dis 19 2012 313 319
28. L. Lo Muzio, A. Santarelli, G. Campisi, M. Lacaita, and G. Favia Possible link between Hashimoto's thyroiditis and oral lichen planus: a novel association found Clin Oral Investig 17 2013 333 336
29. V.S. Pua, R.A. Scolyer, and R.S. Barnetson Pravastatin-induced lichenoid drug eruption Australas J Dermatol 47 2006 57 59
30. D. Roger, F. Rolle, F. Labrousse, A. Brosset, and J.M. Bonnetblanc Simvastatin-induced lichenoid drug eruption Clin Exp Dermatol 19 1994 88 89
31. B. Sebok, M. Toth, B. Anga, F. Harangi, and I. Schneider Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin) Acta Derm Venereol 84 2004 229 230
32. C. Gomez Fernandez, E. Sendagorta Cudos, B. Casado Verrier, M. Feito Rodriguez, J. Suarez Aguado, and C. Vidaurrazaga Diaz de Arcaya Oral lichenoid eruption associated with imatinib treatment Eur J Dermatol 20 2010 127 128
33. J.C. Pascual, J. Matarredona, J. Miralles, V. Conesa, and J. Borras-Blasco Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases Int J Dermatol 45 2006 1471 1473
34. D.S. Lim, and J. Muir Oral lichenoid reaction to imatinib (STI 571, Gleevec) Dermatology 205 2002 169 171
35. M. Wahiduzzaman, and M. Pubalan Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review Dermatol Online J 14 2008 14
36. P. Ena, F. Chiarolini, G.M. Siddi, and A. Cossu Oral lichenoid eruption secondary to imatinib (Glivec) J Dermatolog Treat 15 2004 253 255
37. B.S. Mann, J.R. Johnson, R. Kelly, R. Sridhara, G. Williams, and R. Pazdur Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen Clin Cancer Res 11 2005 5671 5677
38. MedFacts.com. MedFacts meta-analysis covering adverse side effect reports of letrozole patients who developed lichenoid keratosis. 2013 [cited 2013 3/1/2014. Available at: http://medsfacts.com/study-LETROZOLE-causing-LICHENOIDKERATOSIS.php. Accessed March 1, 2014.
39. M.E. Grossman, K. Warren, A. Mady, and K.H. Satra Lichenoid eruption associated with ethambutol J Am Acad Dermatol 33 1995 675 676
40. C. Choonhakarn, and J. Janma Pyrazinamide-induced lichenoid photodermatitis J Am Acad Dermatol 40 1999 645 646
41. R.J. Lehloenya, G. Todd, L. Mogotlane, N. Gantsho, C. Hlela, and K. Dheda Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy J Antimicrob Chemother 67 2012 2535 2537
42. J.W. Byun, C.Y. Bang, G.S. Choi, and J. Shin Lichenoid eruption associated with antituberculous drug: an unusual oral and follicular involvement Am J Dermatopathol 36 2013 684 685
43. W. Bakkour, and I.H. Coulson GA101 (a novel anti-CD20 monoclonal antibody)-induced lichenoid eruption Dermatol Ther (Heidelb) 2 2012 3
44. A. Asarch, A.B. Gottlieb, and J. Lee Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists J Am Acad Dermatol 61 2009 104 111
45. A.C. Moss, N.S. Treister, D.K. Marsee, and A.S. Cheifetz Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab Gastroenterology 132 2007 488 829
46. F. Mocciaro, A. Orlando, S. Renna, M.R. Rizzuto, and M. Cottone Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease J Crohns Colitis 5 2011 173 174
47. D.F. Fiorentino The yin and yang of TNF-α inhibition Arch Dermatol 143 2007 233 236
48. E. Ozkaya-Bayazit Specific site involvement in fixed drug eruption J Am Acad Dermatol 49 2003 1003 1007
49. E. Ozkaya Oral mucosal fixed drug eruption: characteristics and differential diagnosis J Am Acad Dermatol 69 2013 e51 e58
50. V.K. Jain, and V.B. Dixit Archana. Fixed drug eruption of the oral mucous membrane Ann Dent 50 1991 9 11
51. C.H. Pionetti, M.C. Kien, and A. Alonso Fixed drug eruption due to loratadine Allergol Immunopathol (Madr) 31 2003 291 293
52. A.C. Inamadar, A. Palit, S.B. Athanikar, V.V. Sampagavi, and N.S. Deshmukh Multiple fixed drug eruptions due to cetirizine Br J Dermatol 147 2002 1025 1026
53. V.K. Mahajan, N.L. Sharma, and V.C. Sharma Fixed drug eruption: a novel side-effect of levocetirizine Int J Dermatol 44 2005 796 798
54. C. Gomez-Traseira, P. Rojas-Perez-Ezquerra, and L. Sanchez-Morillas Paracetamol-induced fixed drug eruption at an unusual site Recent Pat Inflamm Allergy Drug Discov 7 2013 268 270
55. A. Mahendra, S. Gupta, S. Gupta, S. Sood, and P. Kumar Oral fixed drug eruption due to fluconazole Indian J Dermatol Venereol Leprol 72 2006 391
56. H. Heikkila, K. Timonen, and S. Stubb Fixed drug eruption due to fluconazole J Am Acad Dermatol 42 2000 883 884
57. J.C. Alonso, A.C. Melgosa, M.J. Gonzalo, and C.M. Garcia Fixed drug eruption on the tongue due to clarithromycin Contact Dermatitis 53 2005 121 122
58. S. Gupta, S. Gupta, A. Mittal, and S. David Oral fixed drug eruption caused by gabapentin J Eur Acad Dermatol Venereol 23 2009 1207 1208
59. S. Boulinguez, S. Reix, and C. Bedane Role of drug exposure in aphthous ulcers: a case-control study Br J Dermatol 143 2000 1261 1265
60. M.A. Siegel, and B.A. Balciunas Medication can induce severe ulcerations J Am Dent Assoc 122 1991 75 77
61. C.M. Healy, and M.H. Thornhill An association between recurrent oro-genital ulceration and non-steroidal anti-inflammatory drugs J Oral Pathol Med 24 1995 46 48
62. P. Lisi, K. Hansel, and D. Assalve Aphthous stomatitis induced by piroxicam J Am Acad Dermatol 50 2004 648 649
63. M.J. Trujillo, M. de Barrio, and A. Rodriguez Piroxicam-induced photodermatitis. Cross-reactivity among oxicams. A case report Allergol Immunopathol (Madr) 29 2001 133 136
64. J.V. Bagan, K. Thongprasom, and C. Scully Adverse oral reactions associated with the COX-2 inhibitor rofecoxib Oral Dis 10 2004 401 403
65. E. Goffin, J.M. Pochet, P. Lejuste, and J.F. De Plaen Aphtous ulcers of the mouth associated with losartan Clin Nephrol 50 1998 197
66. F. Martins, M.A. de Oliveira, and Q. Wang A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients Oral Oncol 49 2013 293 298
67. M.A. de Oliveira, E.M.F. Martins, and Q. Wang Clinical presentation and management of mTOR inhibitor-associated stomatitis Oral Oncol 47 2011 998 1003
68. S. Sonis, N. Treister, S. Chawla, G. Demetri, and F. Haluska Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients Cancer 116 2010 210 215
69. W.S. Susser, D.L. Whitaker-Worth, and J.M. Grant-Kels Mucocutaneous reactions to chemotherapy J Am Acad Dermatol 40 1999 367 398 quiz 399-400
70. R.M. Logan, A.M. Stringer, J.M. Bowen, R.J. Gibson, S.T. Sonis, and D.M. Keefe Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63 2009 239 251
71. S.T. Sonis Regimen-related gastrointestinal toxicities in cancer patients Curr Opin Support Palliat Care 4 2010 26 30
72. T. Apostolou, G. Tsagalis, G. Koutroubas, V. Hadjiconstantinou, and S. Drakopoulos Mycophenolate mofetil and oral ulcerations Transplantation 77 2004 1911 1912
73. V. Garrigue, S. Canet, and O. Dereure Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? Transplantation 72 2001 968 969
74. J. Naranjo, J. Poniachik, and D. Cisco Oral ulcers produced by mycophenolate mofetil in two liver transplant patients Transplant Proc 39 2007 612 614
75. R.R. Weng, C.E. Foster 3rd, L.L. Hsieh, and P.R. Patel Oral ulcers associated with mycophenolate mofetil use in a renal transplant recipient Am J Health Syst Pharm 68 2011 585 588
76. G. Hernandez, C. Jimenez, L. Arriba, E. Moreno, and M. Lucas Resolution of oral ulcerations after decreasing the dosage of tacrolimus in a liver transplantation recipient Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 2001 526 531
77. A. Macario-Barrel, S. Tanasescu, and P. Courville Mouth ulcers in patients receiving tacrolimus Ann Dermatol Venereol 128 2001 1327 1329
78. M.D. Mignogna, G. Fortuna, S. Leuci, A. Pollio, and E. Ruoppo Sunitinib adverse event: oral bullous and lichenoid mucositis Ann Pharmacother 43 2009 546 547
79. R. Wolf, and S. Brenner An active amide group in the molecule of drugs that induce pemphigus: a casual or causal relationship? Dermatology 189 1994 1 4
80. S. Vassileva Drug-induced pemphigoid: bullous and cicatricial Clin Dermatol 16 1998 379 387
81. R. Weller, and M.I. White Bullous pemphigoid and penicillamine Clin Exp Dermatol 21 1996 121 122
82. E. Eisenberg, M. Ballow, S.H. Wolfe, D.J. Krutchkoff, and J.M. Tanzer Pemphigus-like mucosal lesions: a side effect of penicillamine therapy Oral Surg Oral Med Oral Pathol 51 1981 409 414
83. H. Matz, A. Bialy-Golan, and S. Brenner Diclofenac: a new trigger of pemphigus vulgaris? Dermatology 195 1997 48 49
84. C. Wijeratne, and P. Webster Risperidone and bullous pemphigoid Am J Psychiatry 153 1996 735
85. T.F. Downham 3rd Spironolactone-induced lichen planus JAMA 240 1978 1138
86. G. Heydenreich, T. Pindborg, and H. Schmidt Bullous dermatosis among patients with chronic renal failure of high dose frusemide Acta Med Scand 202 1977 61 64
87. E.J. Price, and P.J. Venables Drug-induced lupus Drug Saf 12 1995 283 290
88. S. Subramanian, V. Yajnik, B.E. Sands, G. Cullen, and J.R. Korzenik Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent Inflamm Bowel Dis 17 2011 99 104
89. R. Perez-Alvarez, M. Perez-de-Lis, and M. Ramos-Casals Biologics-induced autoimmune diseases Curr Opin Rheumatol 25 2013 56 64
90. L. Ayangco, and R.S. Rogers 3rd Oral manifestations of erythema multiforme Dermatol Clin 21 2003 195 205
91. P.C. Schalock, J.B. Brennick, and J.G. Dinulos Mycoplasma pneumoniae infection associated with bullous erythema multiforme J Am Acad Dermatol 52 2005 705 706
92. A. Auquier-Dunant, M. Mockenhaupt, L. Naldi, O. Correia, W. Schroder, and J.C. Roujeau Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study Arch Dermatol 138 2002 1019 1024
93. D. Edwards, E. Boritz, E.W. Cowen, and R.S. Brown Erythema multiforme major following treatment with infliximab Oral Surg Oral Med Oral Pathol Oral Radiol 115 2013 e36 e40
94. J. Ahdout, J.C. Haley, and M.W. Chiu Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis J Am Acad Dermatol 62 2010 874 879
95. K.E. Abou-Elhamd Two cases of Stevens-Johnson syndrome following intake of klavox with review of literature Eur Arch Otorhinolaryngol 266 2009 1327 1330
96. A.O. Kandil, T. Dvorak, J. Mignano, J.K. Wu, and J.J. Zhu Multifocal Stevens-Johnson syndrome after concurrent phenytoin and cranial and thoracic radiation treatment, a case report Radiat Oncol 5 2010 49
97. O. Hilas, and L. Charneski Lamotrigine-induced Stevens-Johnson syndrome Am J Health Syst Pharm 64 2007 273 275
98. S.I. Hung, W.H. Chung, and S.H. Jee Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions Pharmacogenet Genomics 16 2006 297 306
99. K. Kulkantrakorn, W. Tassaneeyakul, and S. Tiamkao HLA-B∗1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain Pain Pract 12 2012 202 208
100. S.I. Hung, W.H. Chung, and L.B. Liou HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proc Natl Acad Sci U S A 102 2005 4134 4139
101. C. Lonjou, N. Borot, and P. Sekula A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs Pharmacogenet Genomics 18 2008 99 107
102. S. Mallal, D. Nolan, and C. Witt Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 2002 727 732
103. A. Allegra, A. Alonci, and G. Penna Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options Hematol Oncol 30 2012 41 45
104. J.C. Roujeau, J.P. Kelly, and L. Naldi Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis N Engl J Med 333 1995 1600 1607
105. M. Mockenhaupt, C. Viboud, and A. Dunant Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study J Invest Dermatol 128 2008 35 44
106. R.B. Reddy, P.C. Shekar, K.L. Chandra, and R. Aravind Oral lesions associated with Nevirapine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of 10 cases J Oral Maxillofac Pathol 17 2013 431 435
107. M. Pretel Irazabal, L. Marques Martin, L. Aguado Gil, and M.A. Idoate Gastearena Tranexamic acid-induced toxic epidermal necrolysis Ann Pharmacother 47 2013 e16
108. S. Lowndes, A. Darby, G. Mead, and A. Lister Stevens-Johnson syndrome after treatment with rituximab Ann Oncol 13 2002 1948 1950
109. N.S. Treister, D. Magalnick, and S.B. Woo Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 2004 718 725
110. N. Okada, S. Sato, T. Sasou, M. Aoyama, K. Nishida, and K. Yoshikawa Characterization of pigmented granules in minocycline-induced cutaneous pigmentation: observations using fluorescence microscopy and high-performance liquid chromatography Br J Dermatol 129 1993 403 407
111. J.S. Giansanti, D.E. Tillery, and S. Olansky Oral mucosal pigmentation resulting from antimalarial therapy Oral Surg Oral Med Oral Pathol 31 1971 66 69
112. C.L. Kleinegger, H.L. Hammond, and M.W. Finkelstein Oral mucosal hyperpigmentation secondary to antimalarial drug therapy Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90 2000 189 194
113. M.A. Lerman, N. Karimbux, K.A. Guze, and S.B. Woo Pigmentation of the hard palate Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107 2009 8 12
114. J.A. Chiappinelli, and R.E. Walton Tooth discoloration resulting from long-term tetracycline therapy: a case report Quintessence Int 23 1992 539 541
115. L.W. Westbury, and A. Najera Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature J Periodontol 68 1997 84 91
116. B. Arora, L. Kumar, A. Sharma, J. Wadhwa, and V. Kochupillai Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate Ann Oncol 15 2004 358 359
117. C.C. Li, S.M. Malik, and B.F. Blaeser Mucosal pigmentation caused by imatinib: report of three cases Head Neck Pathol 6 2012 290 295
118. G. Tadini, M. D'Orso, M. Cusini, and E. Alessi Oral mucosa pigmentation: a new side effect of azidothymidine therapy in patients with acquired immunodeficiency syndrome Arch Dermatol 127 1991 267 268
119. G. Ficarra, E.J. Shillitoe, and K. Adler-Storthz Oral melanotic macules in patients infected with human immunodeficiency virus Oral Surg Oral Med Oral Pathol 70 1990 748 755
120. R.S. Hertz, P.C. Beckstead, and W.J. Brown Epithelial melanosis of the gingiva possibly resulting from the use of oral contraceptives J Am Dent Assoc 100 1980 713 714
121. M. Blaya, and N. Saba Images in clinical medicine. Chemotherapy-induced hyperpigmentation of the tongue N Engl J Med 365 2011 e20
122. M. Alfreijat Tongue hyperpigmentation associated with chemotherapy J Community Hosp Intern Med Perspect 3 2013
123. K.M. Casamiquela, and P.R. Cohen Chemotherapy-associated tongue hyperpigmentation and blue lunula J Drugs Dermatol 12 2013 223 226
124. W.A. Gonzalez-Arriagada, A.R. Silva, P.A. Vargas, O.P. de Almeida, and M.A. Lopes Facial pigmentation associated with amiodarone Gen Dent 61 2013 e15 e17
125. M.E. Wolf, S. Richer, M.A. Berk, and A.D. Mosnaim Cutaneous and ocular changes associated with the use of chlorpromazine Int J Clin Pharmacol Ther Toxicol 31 1993 365 367
126. S. Pradhan, and P. Mishra Gingival enlargement in antihypertensive medication JNMA J Nepal Med Assoc 48 2009 149 152
127. P. Westbrook, E.M. Bednarczyk, M. Carlson, H. Sheehan, and N.F. Bissada Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine J Periodontol 68 1997 645 650
128. R.A. Seymour, J.M. Thomason, and J.S. Ellis The pathogenesis of drug-induced gingival overgrowth J Clin Periodontol 23 1996 165 175
129. R.S. Brown, W.T. Beaver, and W.K. Bottomley On the mechanism of drug-induced gingival hyperplasia J Oral Pathol Med 20 1991 201 209
130. R. Arya, S. Gulati, M. Kabra, J.K. Sahu, and V. Kalra Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children Neurology 76 2011 1338 1343
131. S. Vahabi, B.N. Salman, F. Rezazadeh, and M. Namdari Effects of cyclosporine and phenytoin on biomarker expressions in gingival fibroblasts of children and adults: an in vitro study J Basic Clin Physiol Pharmacol 25 2014 167 173
132. L. Lee, P.A. Miller, W.G. Maxymiw, H.A. Messner, and L.E. Rotstein Intraoral pyogenic granuloma after allogeneic bone marrow transplant. Report of three cases Oral Surg Oral Med Oral Pathol 78 1994 607 610
133. M. Al-Mohaya, N. Treister, O. Al-Khadra, L. Lehmann, B. Padwa, and S.B. Woo Calcineurin inhibitor-associated oral inflammatory polyps after transplantation J Oral Pathol Med 36 2007 570 574
134. M. Kataoka, Y. Shimizu, and K. Kunikiyo Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth J Cell Physiol 182 2000 351 358
135. G.P. Schincaglia, F. Forniti, R. Cavallini, R. Piva, G. Calura, and L. del Senno Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 21 1992 181 185
136. S.B. Woo, C.M. Allen, A. Orden, D. Porter, and J.H. Antin Non-gingival soft tissue growths after allogeneic marrow transplantation Bone Marrow Transplant 17 1996 1127 1132
137. A.M. Iacopino, D. Doxey, and C.W. Cutler Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia J Periodontol 68 1997 73 83
138. N. Bostanci, T. Ilgenli, and D.C. Pirhan Relationship between IL-1 A polymorphisms and gingival overgrowth in renal transplant recipients receiving cyclosporin A J Clin Periodontol 33 2006 771 778
139. R.S. Morton, and A.I. Dongari-Bagtzoglou Regulation of gingival fibroblast interleukin-6 secretion by cyclosporine A J Periodontol 70 1999 1464 1471
140. Q.T. Le, H.E. Kim, and C.J. Schneider Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study J Clin Oncol 29 2011 2808 2814
141. D. Lauritano, M. Petruzzi, D. Di Stasio, and A. Lucchese Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study Int J Oral Sci 6 2013 27 30
142. A.W. Beaven, and T.C. Shea Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant Drugs Today (Barc) 43 2007 461 473
143. M.A. Lerman, and N.S. Treister Generalized white appearance of the oral mucosa. Hyperkeratosis secondary to palifermin J Am Dent Assoc 141 2010 867 869
144. C.C. Boer, M.E. Correa, E.C. Miranda, and C.A. de Souza Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT Bone Marrow Transplant 45 2010 705 711
145. J.B. Epstein, N. Phillips, J. Parry, M.S. Epstein, T. Nevill, and P. Stevenson-Moore Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation Bone Marrow Transplant 2002 785 792
146. M. Tuccori, F. Lapi, and A. Testi Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting Drug Saf 34 2011 849 859
147. R.I. Henkin Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction Drug Saf 11 1994 318 377
148. A. Sekulic, M.R. Migden, and A.E. Oro Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 2012 2171 2179
149. Y. Han, and M.T. Smith Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN) Front Pharmacol 4 2013 156
150. D.L. Hershman, L.H. Weimer, and A. Wang Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy Breast Cancer Res Treat 125 2011 767 774
151. S.B. Park, D. Goldstein, and A.V. Krishnan Chemotherapy-induced peripheral neurotoxicity: a critical analysis CA Cancer J Clin 63 2013 419 437
152. M. Dorchin, R. Masoumi Dehshiri, S. Soleiman, and M. Manashi Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and acute lymphoblastic leukemia Iran J Ped Hematol Oncol 3 2013 138 142
153. G. Dixit, A. Dhingra, and D. Kaushal Vincristine induced cranial neuropathy J Assoc Physicians India 60 2012 56 58
154. B.V. Burns, and J.C. Shotton Vocal fold palsy following vinca alkaloid treatment J Laryngol Otol 112 1998 485 487
155. R. Naithani, T.K. Dolai, and R. Kumar Bilateral vocal cord paralysis following treatment with vincristine Indian Pediatr 46 2009 68 69
156. A.D. Lipworth, C. Robert, and A.X. Zhu Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib Oncology 77 2009 257 271
157. W.J. Lee, J.L. Lee, and S.E. Chang Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib Br J Dermatol 161 2009 1045 1051
158. C. Kollmannsberger, G. Bjarnason, and P. Burnett Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities Oncologist 16 2011 543 553
159. S.L. Ruggiero, and B. Mehrotra Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management Annu Rev Med 60 2009 85 96
160. S. Otto, S. Baumann, M. Ehrenfeld, and C. Pautke Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection J Craniomaxillofac Surg 41 2013 694 698
161. T.D. Rachner, U. Platzbecker, D. Felsenberg, and L.C. Hofbauer Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy Mayo Clin Proc 88 2013 418 419
162. R.E. Marx, Y. Sawatari, M. Fortin, and V. Broumand Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 2005 1567 1575
163. S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg, and S.L. Engroff Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 62 2004 527 534
164. S.B. Woo, J.W. Hellstein, and J.R. Kalmar Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws Ann Intern Med 144 2006 753 761
165. S.B. Woo, H. Mawardi, and N. Treister Comments on Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification Oral Oncol 45 2009 740
166. S.L. Ruggiero, T.B. Dodson, L.A. Assael, R. Landesberg, R.E. Marx, and B. Mehrotra American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update J Oral Maxillofac Surg 67 2009 2 12
167. J. Wood, K. Bonjean, and S. Ruetz Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 302 2002 1055 1061
168. C.L. Estilo, M. Fornier, A. Farooki, D. Carlson, G. Bohle 3rd, and J.M. Huryn Osteonecrosis of the jaw related to bevacizumab J Clin Oncol 26 2008 4037 4038
169. V. Guarneri, D. Miles, and N. Robert Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer Breast Cancer Res Treat 122 2010 181 188
170. S. Katsenos, C. Christophylakis, and K. Psathakis Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab Arch Bronconeumol 48 2012 218 219
171. S. Hoefert, and H. Eufinger Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110 2010 463 469
172. F.P. Koch, C. Walter, T. Hansen, E. Jager, and W. Wagner Osteonecrosis of the jaw related to sunitinib Oral Maxillofac Surg 15 2011 63 66
173. Y. Fleissig, E. Regev, and H. Lehman Sunitinib related osteonecrosis of jaw: a case report Oral Surg Oral Med Oral Pathol Oral Radiol 113 2012 e1 e3
174. T. Smidt-Hansen, T.B. Folkmar, K. Fode, M. Agerbaek, and F. Donskov Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma J Oral Maxillofac Surg 71 2013 1532 1540
175. A. Agrillo, E. Nastro Siniscalchi, A. Facchini, F. Filiaci, and C. Ungari Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports Eur Rev Med Pharmacol Sci 16 2012 952 957
176. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
177. C. Christodoulou, A. Pervena, and G. Klouvas Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone Oncology 76 2009 209 211
178. T. Okui, T. Shimo, and T. Fukazawa Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction Mol Cancer Ther 9 2010 2960 2969
179. F. Giancola, G. Campisi, L.L. Russo, L.L. Muzio, and O. Di Fede Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol (Roma) 4 2013 20 21
180. C. Scully, M. el-Kabir, and L.P. Samaranayake Candida and oral candidosis: a review Crit Rev Oral Biol Med 5 1994 125 157
181. S. Dreizen, M.J. Keating, and M. Beran Orofacial fungal infections. Nine pathogens that may invade during chemotherapy Postgrad Med 91 1992 349 350 353-354, 357-360 passim
182. F. Al Akhrass, L. Debiane, and L. Abdallah Palatal mucormycosis in patients with hematologic malignancy and stem cell transplantation Med Mycol 49 2011 400 405
183. K. Marsot-Dupuch, J. Quillard, and M.C. Meyohas Head and neck lesions in the immunocompromised host Eur Radiol 14 2004 E155 E167
184. M.M. Schubert Oral manifestations of viral infections in immunocompromised patients Curr Opin Dent 1 1991 384 397
185. D. Triantos, S.R. Porter, C. Scully, and C.G. Teo Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance Clin Infect Dis 25 1997 1392 1396
186. R.S. Pinheiro, T.R. de Franca, and B. Rocha Human papillomavirus coinfection in the oral cavity of HIV-infected children J Clin Pathol 64 2011 1083 1087
187. G. Samonis, E. Mantadakis, and S. Maraki Orofacial viral infections in the immunocompromised host Oncol Rep 7 2000 1389 1394
188. E.T. Stoopler, and M.S. Greenberg Update on herpesvirus infections Dent Clin North Am 47 2003 517 532
189. P. Deepak, D.J. Stobaugh, and E.D. Ehrenpreis Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System J Gastrointestin Liver Dis 22 2013 269 276
190. I. Delabaye, and F. De Keyser 74-wk follow-up of safety of infliximab in patients with refractory rheumatoid arthritis Arthritis Res Ther 12 2010 R121
191. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285
192. E.M. Salvana, and R.A. Salata Infectious complications associated with monoclonal antibodies and related small molecules Clin Microbiol Rev 22 2009 274 290 Table of Contents
193. K.A. Hom, R. Hirsch, and R.G. Elluru Antihypertensive drug-induced angioedema causing upper airway obstruction in children Int J Pediatr Otorhinolaryngol 76 2012 14 19
194. M.S. Rafii, M. Koenig, and W.C. Ziai Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke Neurology 65 2005 1906
195. M. Shino, K. Takahashi, T. Murata, H. Iida, Y. Yasuoka, and N. Furuya Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis Am J Otolaryngol 32 2011 624 626
196. J. Southward, E. Irvine, and M. Rabinovich Probable amlodipine-induced angioedema Ann Pharmacother 43 2009 772 776
197. J.M. Ruscin, R.L. Page 2nd, and J. Scott Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature Am J Geriatr Pharmacother 4 2006 325 329
198. T.C. Fischer, M. Worm, and D.A. Groneberg Clopidogrel-associated angioedema Am J Med 114 2003 77 78
199. S.A.A.K. Nisly, and T.B. Knight Simvastatin: a risk factor for angioedema? J Pharmacy Technol 29 2013 149 152
200. M.I. Liebhaber, R.S. Wright, H.J. Gelberg, Z. Dyer, and J.L. Kupperman Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases Chest 115 1999 886 889
201. Insert P. Lipitor (atorvastatin). 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020702s057lbl.pdf. Accessed April 1, 2014.
202. J.P. Hampson, D. Smith, R. Cowell, and A. Baker Hypotension and eosinophilia with atorvastatin Pharm World Sci 27 2005 279 280
203. A. Bagg, and C.H. Dunphy Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders Semin Diagn Pathol 30 2013 102 112
204. Y. Hoshida, J.X. Xu, and S. Fujita Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication J Rheumatol 34 2007 322 331
205. H. Hanakawa, Y. Orita, Y. Sato, K. Uno, K. Nishizaki, and T. Yoshino Large ulceration of the oropharynx induced by methotrexate-associated lymphoproliferative disorders Acta Med Okayama 67 2013 265 269
206. A. Ichikawa, F. Arakawa, and J. Kiyasu Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression Eur J Haematol 91 2013 20 28
207. K. Kikuchi, Y. Miyazaki, and A. Tanaka Methotrexate-related Epstein-Barr virus (EBV)-associated lymphoproliferative disorder - so-called "Hodgkin-like lesion" - of the oral cavity in a patient with rheumatoid arthritis Head Neck Pathol 4 2010 305 311
208. A. Kalantzis, Z. Marshman, D.T. Falconer, P.R. Morgan, and E.W. Odell Oral effects of low-dose methotrexate treatment Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 2005 52 62
209. Y. Niwa, T. Terashima, and H. Sumi Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin Br J Dermatol 149 2003 960 967
210. U. Mattsson, B. Magnusson, and M. Jontell Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110 2010 e19 e25
211. J.C. Becker, R. Houben, C.S. Vetter, and E.B. Brocker The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report BMC Cancer 6 2006 7
212. C.D. Wimmer, M.K. Angele, and B. Schwarz Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients Transpl Int 26 2013 999 1006
213. T.G. Berger, M. Duvic, A.S. Van Voorhees, M.J. VanBeek, and I.J. Frieden The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force J Am Acad Dermatol 54 2006 818 823
214. P. Tennis, J.M. Gelfand, and K.J. Rothman Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors Br J Dermatol 165 2011 465 473
215. G. Fischer, and J. Bradford Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report J Reprod Med 52 2007 329 331
216. T. Langeland, and V. Engh Topical use of tacrolimus and squamous cell carcinoma on the penis Br J Dermatol 152 2005 183 185
217. D. Mabrouk, H.M. Gurcan, D.B. Keskin, W.G. Christen, and A.R. Ahmed Association between cancer and immunosuppressive therapy - analysis of selected studies in pemphigus and pemphigoid Ann Pharmacother 44 2010 1770 1776
218. J.P. Leombruno, T.R. Einarson, and E.C. Keystone The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 2009 1136 1145
219. E. Baecklund, C. Backlin, and A. Iliadou Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis Arthritis Rheum 54 2006 3774 3781
220. H. Mawardi, S. Elad, and M.E. Correa Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes Bone Marrow Transplant 46 2011 884 891